{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T09:46:10Z","timestamp":1790934370880,"version":"4.1.0"},"reference-count":51,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T00:00:00Z","timestamp":1778803200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["1K23AI185318-01A1"],"award-info":[{"award-number":["1K23AI185318-01A1"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Botica Research Scholar Fund"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Invasive fungal sinusitis (IFS) profoundly impacts individuals with hematological malignancies, with rapid progression and high mortality rates. In an evolving therapeutic landscape, outcomes for patients with hematological malignancies who develop IFS warrant further evaluation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We performed a descriptive case series and retrospective review of patients with hematologic malignancies who developed proven IFS (per European Organization for Research and Treatment of Cancer\/Mycoses Study Group criteria) between 2005 and 2024 at a tertiary academic center. Clinical data and outcomes were collected from electronic medical records. Statistical analyses included Fisher exact tests, t tests, or Wilcoxon rank-sum tests. Kaplan-Meier curves were used to estimate survival probability, and log-rank tests were compared across groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Thirty-one patients with confirmed IFS were identified. Most patients had acute myeloid leukemia (61.3%) and received cytotoxic chemotherapy (96.8%). Targeted oncologic therapies included BCL2 inhibitors (29.0%), FLT3 inhibitors (19.4%), antibody-based therapies (12.9%), BTK inhibitors (6.4%), and antibody\u2013drug conjugates (6.4%). The most common fungal isolates were Aspergillus (22.6%), Fusarium (16.1%), and Rhizopus (9.7%). Amphotericin B (96.8%) and voriconazole (71.0%) were frequently used, and newer antifungals included isavuconazole (38.7%), olorofim (3.3%), and fosmanogepix (3.3%). Necrotic tissue (45.2%) and mucosal thickening (87.1%) were common on sinonasal endoscopy and computed tomography scan, respectively. Orbital (25.8%) and intracranial (9.7%) extension occurred in a minority. Most patients underwent functional endoscopic sinus surgery (80.6%). Serum fungal biomarkers were infrequently positive, with (1,3)-\u00df-D-glucan in 19.4% and galactomannan in 9.7%. Overall mortality was 71.0% at the end of the study period, with a median survival (interquartile range) of 101 (21\u2013299) days. Mortality was 22.6% at 1 month, 25.8% at 2 months, 32.3% at 3 months, 41.9% at 6 months, 54.8% at 1 year, 58.1% at 2 years, and 64.5% at 3 years.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Despite novel therapies and aggressive surgical interventions, patients with IFS had high mortality.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ofid\/ofag304","type":"journal-article","created":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T12:07:26Z","timestamp":1778760446000},"source":"Crossref","is-referenced-by-count":2,"title":["Invasive Fungal Sinusitis in Patients With Hematological Malignancies: A 20-Year Study From a Tertiary Academic US Hospital System"],"prefix":"10.1093","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6336-0826","authenticated-orcid":false,"given":"Tejas S","family":"Athni","sequence":"first","affiliation":[{"name":"Harvard Medical School , Boston, Massachusetts ,","place":["USA"]},{"name":"Department of Epidemiology, Harvard T.H. Chan School of Public Health , Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn B","family":"Strauch","sequence":"additional","affiliation":[{"name":"Department of Medicine, Beth Israel Deaconess Medical Center , Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1811-6565","authenticated-orcid":false,"given":"Victor","family":"Kovac","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Brigham and Women's Hospital , Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6264-423X","authenticated-orcid":false,"given":"Esther","family":"Arbona-Haddad","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Brigham and Women's Hospital , Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1760-0427","authenticated-orcid":false,"given":"Inia Perez","family":"Villa","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Brigham and Women's Hospital , Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2006-1236","authenticated-orcid":false,"given":"Simran","family":"Gupta","sequence":"additional","affiliation":[{"name":"Harvard Medical School , Boston, Massachusetts ,","place":["USA"]},{"name":"Division of Infectious Diseases, Brigham and Women's Hospital , Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muneerah M","family":"Aleissa","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Brigham and Women's Hospital , Boston, Massachusetts ,","place":["USA"]},{"name":"College of Pharmacy, Department of Pharmacy Practice, Princess Nourah Bint Abdulrahman University , Riyadh ,","place":["Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-6616-920X","authenticated-orcid":false,"given":"Alexis D","family":"Liakos","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Brigham and Women's Hospital , Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-7361-1809","authenticated-orcid":false,"given":"Alexandra","family":"Tong","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Brigham and Women's Hospital , Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahul S","family":"Vedula","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana Farber Cancer Institute , Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice Z","family":"Maxfield","sequence":"additional","affiliation":[{"name":"Harvard Medical School , Boston, Massachusetts ,","place":["USA"]},{"name":"Division of Otolaryngology-Head and Neck Surgery, Brigham and Women's Hospital , Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Regan W","family":"Bergmark","sequence":"additional","affiliation":[{"name":"Harvard Medical School , Boston, Massachusetts ,","place":["USA"]},{"name":"Division of Otolaryngology-Head and Neck Surgery, Brigham and Women's Hospital , Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6075-3990","authenticated-orcid":false,"given":"Amy C","family":"Sherman","sequence":"additional","affiliation":[{"name":"Harvard Medical School , Boston, Massachusetts ,","place":["USA"]},{"name":"Division of Infectious Diseases, Brigham and Women's Hospital , Boston, Massachusetts ,","place":["USA"]},{"name":"Department of Medical Oncology, Dana Farber Cancer Institute , Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,5,15]]},"reference":[{"key":"2026060214262629800_ofag304-B1","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1056\/NEJM199707243370407","article-title":"Fungal sinusitis","volume":"337","author":"deShazo","year":"1997","journal-title":"N Engl J Med"},{"key":"2026060214262629800_ofag304-B2","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s00277-002-0466-3","article-title":"Invasive fungal infections in hematology: new trends","volume":"81","author":"Martino","year":"2002","journal-title":"Ann Hematol"},{"key":"2026060214262629800_ofag304-B3","doi-asserted-by":"crossref","first-page":"2473974X211002547","DOI":"10.1177\/2473974X211002547","article-title":"Perioperative indicators of prognosis in acute invasive fungal sinusitis","volume":"5","author":"Gardner","year":"2021","journal-title":"OTO Open"},{"key":"2026060214262629800_ofag304-B4","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1111\/myc.12884","article-title":"Fungal infections of the central nervous system and paranasal sinuses in onco-haematologic patients. Epidemiological study reporting the diagnostic-therapeutic approach and outcome in 89 cases","volume":"62","author":"Candoni","year":"2019","journal-title":"Mycoses"},{"key":"2026060214262629800_ofag304-B5","doi-asserted-by":"crossref","first-page":"3688","DOI":"10.1038\/s41598-020-60719-7","article-title":"Treatment outcomes in acute invasive fungal rhinosinusitis extending to the extrasinonasal area","volume":"10","author":"Nam","year":"2020","journal-title":"Sci Rep"},{"key":"2026060214262629800_ofag304-B6","doi-asserted-by":"crossref","first-page":"e841","DOI":"10.1016\/j.ijid.2011.08.005","article-title":"Prognosis of acute invasive fungal rhinosinusitis related to underlying disease","volume":"15","author":"Valera","year":"2011","journal-title":"Int J Infect Dis"},{"key":"2026060214262629800_ofag304-B7","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1002\/lary.23912","article-title":"Survival outcomes in acute invasive fungal sinusitis: a systematic review and quantitative synthesis of published evidence: survival outcomes in invasive fungal sinusitis","volume":"123","author":"Turner","year":"2013","journal-title":"Laryngoscope"},{"key":"2026060214262629800_ofag304-B8","doi-asserted-by":"crossref","first-page":"S678","DOI":"10.1093\/cid\/civ819","article-title":"The regulatory pathway for antifungal drugs: a US perspective","volume":"61(Suppl 6)","author":"Tillotson","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2026060214262629800_ofag304-B9","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1177\/0194599815627786","article-title":"Acute invasive fungal rhinosinusitis: a 15-year experience with 41 patients: a 15-year experience with 41 patients","volume":"154","author":"Payne","year":"2016","journal-title":"Otolaryngol Head Neck Surg"},{"key":"2026060214262629800_ofag304-B10","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1002\/lary.20520","article-title":"Fungal rhinosinusitis: a categorization and definitional schema addressing current controversies: a categorization and definitional schema addressing current controversies","volume":"119","author":"Chakrabarti","year":"2009","journal-title":"Laryngoscope"},{"key":"2026060214262629800_ofag304-B11","doi-asserted-by":"crossref","first-page":"319","DOI":"10.3390\/medicina55070319","article-title":"Invasive and non-invasive fungal rhinosinusitis\u2014a review and update of the evidence","volume":"55","author":"Deutsch","year":"2019","journal-title":"Medicina (Kaunas)"},{"key":"2026060214262629800_ofag304-B12","doi-asserted-by":"crossref","first-page":"e176162","DOI":"10.1172\/jci.insight.176162","article-title":"BTK inhibitor-induced defects in human neutrophil effector activity against Aspergillus fumigatus are restored by TNF-\u03b1","volume":"9","author":"Vargas-Blanco","year":"2024","journal-title":"JCI Insight"},{"key":"2026060214262629800_ofag304-B13","doi-asserted-by":"crossref","first-page":"1386517","DOI":"10.3389\/fimmu.2024.1386517","article-title":"Ex vivo characterization of acute myeloid leukemia patients undergoing hypomethylating agents and venetoclax regimen reveals a venetoclax-specific effect on non-suppressive regulatory T cells and bona fide PD-1+TIM3+ exhausted CD8+ T cells","volume":"15","author":"Corradi","year":"2024","journal-title":"Front Immunol"},{"key":"2026060214262629800_ofag304-B14","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1038\/s41419-021-04285-4","article-title":"Venetoclax imparts distinct cell death sensitivity and adaptivity patterns in T cells","volume":"12","author":"Ludwig","year":"2021","journal-title":"Cell Death Dis"},{"key":"2026060214262629800_ofag304-B15","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.medcli.2019.07.026","article-title":"Riesgo de infecci\u00f3n asociada a nuevas terapias para el tratamiento de los s\u00edndromes linfoproliferativos","volume":"154","author":"Los-Arcos","year":"2020","journal-title":"Med Clin (Barc)"},{"key":"2026060214262629800_ofag304-B16","doi-asserted-by":"crossref","first-page":"3719","DOI":"10.3390\/cancers16213719","article-title":"The immunomodulatory effect of different FLT3 inhibitors on dendritic cells","volume":"16","author":"Schlaweck","year":"2024","journal-title":"Cancers (Basel)"},{"key":"2026060214262629800_ofag304-B17","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1056\/NEJMoa1815105","article-title":"Tagraxofusp in blastic plasmacytoid dendritic-cell neoplasm","volume":"380","author":"Pemmaraju","year":"2019","journal-title":"N Engl J Med"},{"key":"2026060214262629800_ofag304-B18","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1001\/jamaoto.2024.0042","article-title":"Prognostic factors for survival using a clinical severity staging system among patients with acute invasive fungal sinusitis","volume":"150","author":"Munyemana","year":"2024","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"key":"2026060214262629800_ofag304-B19","doi-asserted-by":"crossref","first-page":"e0007423","DOI":"10.1128\/cmr.00074-23","article-title":"Novel antifungals and treatment approaches to tackle resistance and improve outcomes of invasive fungal disease","volume":"37","author":"Hoenigl","year":"2024","journal-title":"Clin Microbiol Rev"},{"key":"2026060214262629800_ofag304-B20","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1016\/S1473-3099(25)00224-5","article-title":"Olorofim for the treatment of invasive fungal diseases in patients with few or no therapeutic options: a single-arm, open-label, phase 2b study","volume":"25","author":"Maertens","year":"2025","journal-title":"Lancet Infect Dis"},{"key":"2026060214262629800_ofag304-B21","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1017\/S0022215122000755","article-title":"Risk factors and predictors of mortality in acute invasive fungal sinusitis - a single-institution experience","volume":"136","author":"Varghese","year":"2022","journal-title":"J Laryngol Otol"},{"key":"2026060214262629800_ofag304-B22","doi-asserted-by":"crossref","first-page":"9987871","DOI":"10.1155\/2021\/9987871","article-title":"Acute invasive fungal rhinosinusitis-related orbital infection: a single medical center experience","volume":"2021","author":"Huang","year":"2021","journal-title":"J Ophthalmol"},{"key":"2026060214262629800_ofag304-B23","doi-asserted-by":"crossref","first-page":"4281","DOI":"10.1007\/s00405-016-4109-z","article-title":"Acute invasive fungal rhinosinusitis: our experience with 18 cases","volume":"273","author":"Bakhshaee","year":"2016","journal-title":"Eur Arch Otorhinolaryngol"},{"key":"2026060214262629800_ofag304-B24","doi-asserted-by":"crossref","first-page":"43","DOI":"10.14639\/0392-100X-N0848","article-title":"Definition and management of invasive fungal rhinosinusitis: a single-centre retrospective study","volume":"41","author":"Fadda","year":"2021","journal-title":"Acta Otorhinolaryngol Ital"},{"key":"2026060214262629800_ofag304-B25","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.jcms.2015.12.016","article-title":"Invasive fungal rhinosinusitis in adult patients: our experience in diagnosis and management","volume":"44","author":"Pagella","year":"2016","journal-title":"J Craniomaxillofac Surg"},{"key":"2026060214262629800_ofag304-B26","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1093\/cid\/ciz1008","article-title":"Revision and update of the consensus definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium","volume":"71","author":"Donnelly","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2026060214262629800_ofag304-B27","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.otohns.2007.02.004","article-title":"The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict?","volume":"137","author":"Hopkins","year":"2007","journal-title":"Otolaryngol Head Neck Surg"},{"key":"2026060214262629800_ofag304-B28","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1186\/1471-2334-11-250","article-title":"Invasive fungal sinusitis in patients with hematological malignancy: 15 years experience in a single university hospital in Taiwan","volume":"11","author":"Chen","year":"2011","journal-title":"BMC Infect Dis"},{"key":"2026060214262629800_ofag304-B29","doi-asserted-by":"crossref","first-page":"2899","DOI":"10.1093\/jac\/dkv198","article-title":"Invasive mould sinusitis in patients with haematological malignancies: a 10 year single-centre study","volume":"70","author":"Davoudi","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"2026060214262629800_ofag304-B30","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.otorri.2019.11.004","article-title":"10-year experience in patients operated for acute invasive fungal rhinosinusitis","volume":"71","author":"Lagos","year":"2020","journal-title":"Acta Otorrinolaringol Esp (Engl Ed)"},{"key":"2026060214262629800_ofag304-B31","doi-asserted-by":"crossref","first-page":"856","DOI":"10.3201\/eid2804.211987","article-title":"Rigidoporus corticola colonization and invasive fungal disease in immunocompromised patients, United States","volume":"28","author":"Laga","year":"2022","journal-title":"Emerg Infect Dis"},{"key":"2026060214262629800_ofag304-B32","doi-asserted-by":"crossref","first-page":"100749","DOI":"10.1016\/j.mmcr.2025.100749","article-title":"Invasive fungal sinusitis by Scedosporium boydii in an immunocompromised patient. A case report","volume":"50","author":"Rey-Suarez","year":"2025","journal-title":"Med Mycol Case Rep"},{"key":"2026060214262629800_ofag304-B33","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1177\/194589240401800202","article-title":"Invasive fungal sinusitis: a 15-year review from a single institution","volume":"18","author":"Parikh","year":"2004","journal-title":"Am J Rhinol"},{"key":"2026060214262629800_ofag304-B34","doi-asserted-by":"crossref","first-page":"345","DOI":"10.3390\/jof10050345","article-title":"The role of olorofim in the treatment of filamentous fungal infections: a review of in vitro and in vivo studies","volume":"10","author":"Feuss","year":"2024","journal-title":"J Fungi (Basel)"},{"key":"2026060214262629800_ofag304-B35","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1186\/s12879-024-10143-3","article-title":"Review of the novel antifungal drug olorofim (F901318)","volume":"24","author":"Vanbiervliet","year":"2024","journal-title":"BMC Infect Dis"},{"key":"2026060214262629800_ofag304-B36","first-page":"e59210","article-title":"Fosmanogepix: the novel anti-fungal agent's comprehensive review of in vitro, in vivo, and current insights from advancing clinical trials","volume":"16","author":"Almajid","year":"2024","journal-title":"Cureus"},{"key":"2026060214262629800_ofag304-B37","doi-asserted-by":"crossref","first-page":"e0141922","DOI":"10.1128\/aac.01419-22","article-title":"Clinical efficacy and safety of a novel antifungal, fosmanogepix, in patients with candidemia caused by Candida auris: results from a phase 2 trial","volume":"67","author":"Vazquez","year":"2023","journal-title":"Antimicrob Agents Chemother"},{"key":"2026060214262629800_ofag304-B38","doi-asserted-by":"crossref","first-page":"239","DOI":"10.3390\/jof6040239","article-title":"Fosmanogepix: a review of the first-in-class broad spectrum agent for the treatment of invasive fungal infections","volume":"6","author":"Shaw","year":"2020","journal-title":"J Fungi (Basel)"},{"key":"2026060214262629800_ofag304-B39","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1002\/lary.23978","article-title":"Invasive fungal rhinosinusitis: a 15-year experience with 29 patients: a 15-year experience with 29 patients","volume":"123","author":"Monroe","year":"2013","journal-title":"Laryngoscope"},{"key":"2026060214262629800_ofag304-B40","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1007\/s00405-021-06910-6","article-title":"Clinical and surgical factors affecting the prognosis and survival rates in patients with mucormycosis","volume":"279","author":"G\u00fcr","year":"2022","journal-title":"Eur Arch Otorhinolaryngol"},{"key":"2026060214262629800_ofag304-B41","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1002\/alr.23132","article-title":"Diagnosis, prognosticators, and management of acute invasive fungal rhinosinusitis: multidisciplinary consensus statement and evidence-based review with recommendations","volume":"13","author":"Roland","year":"2023","journal-title":"Int Forum Allergy Rhinol"},{"key":"2026060214262629800_ofag304-B42","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1093\/cid\/cir897","article-title":"\u03b2-glucan antigenemia assay for the diagnosis of invasive fungal infections in patients with hematological malignancies: a systematic review and meta-analysis of cohort studies from the third European Conference on Infections in Leukemia (ECIL-3)","volume":"54","author":"Lamoth","year":"2012","journal-title":"Clin Infect Dis"},{"key":"2026060214262629800_ofag304-B43","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1002\/alr.22225","article-title":"The role of galactomannan Aspergillus antigen in diagnosing acute invasive fungal sinusitis: galactomannan in diagnosis of AIFS","volume":"9","author":"Melancon","year":"2019","journal-title":"Int Forum Allergy Rhinol"},{"key":"2026060214262629800_ofag304-B44","doi-asserted-by":"crossref","first-page":"e0120925","DOI":"10.1128\/spectrum.01209-25","article-title":"Assessment of the 1,3-\u03b2-D-glucan test and the galactomannan antigen test in the detection of invasive fungal infections in patients with hematological diseases","volume":"13","author":"Wei","year":"2025","journal-title":"Microbiol Spectr"},{"key":"2026060214262629800_ofag304-B45","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.cll.2024.10.009","article-title":"Molecular diagnostics for invasive molds: from lab to bedside","volume":"45","author":"Hannaford","year":"2025","journal-title":"Clin Lab Med"},{"key":"2026060214262629800_ofag304-B46","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1177\/0194599818765744","article-title":"Acute invasive fungal rhinosinusitis in immunocompromised patients: role of an early diagnosis","volume":"159","author":"Fernandez","year":"2018","journal-title":"Otolaryngol Head Neck Surg"},{"key":"2026060214262629800_ofag304-B47","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0039-6257(05)80041-4","article-title":"Survival factors in rhino-orbital-cerebral mucormycosis","volume":"39","author":"Yohai","year":"1994","journal-title":"Surv Ophthalmol"},{"key":"2026060214262629800_ofag304-B48","doi-asserted-by":"crossref","first-page":"175","DOI":"10.4274\/tao.2024.2023-10-4","article-title":"Optimizing surgical management of acute invasive fungal sinusitis","volume":"61","author":"Varghese","year":"2023","journal-title":"Turk Arch Otorhinolaryngol"},{"key":"2026060214262629800_ofag304-B49","doi-asserted-by":"crossref","first-page":"767.e1","DOI":"10.1016\/j.joms.2016.11.004","article-title":"Acute invasive fungal rhinosinusitis: presentation of 19 cases, review of the literature, and a new classification system","volume":"75","author":"Ergun","year":"2017","journal-title":"J Oral Maxillofac Surg"},{"key":"2026060214262629800_ofag304-B50","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1002\/alr.22172","article-title":"A multi-institutional review of outcomes in biopsy-proven acute invasive fungal sinusitis: outcomes with IFS","volume":"8","author":"Wandell","year":"2018","journal-title":"Int Forum Allergy Rhinol"},{"key":"2026060214262629800_ofag304-B51","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2500\/ajra.2017.31.4420","article-title":"Complete surgical resection and short-term survival in acute invasive fungal rhinosinusitis","volume":"31","author":"Roxbury","year":"2017","journal-title":"Am J Rhinol Allergy"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofag304\/68290053\/ofag304.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/13\/6\/ofag304\/68290053\/ofag304.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/13\/6\/ofag304\/68290053\/ofag304.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T18:26:39Z","timestamp":1780424799000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofag304\/8678610"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,15]]},"references-count":51,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6,2]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofag304","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,6]]},"published":{"date-parts":[[2026,5,15]]},"article-number":"ofag304"}}